Avalon's Laboratory Services MSO Launches DNA Testing Kit For Predisposition To Opioid Addiction
Avalon's Laboratory Services MSO Launches DNA Testing Kit For Predisposition To Opioid Addiction
阿瓦隆实验室服务MSO推出DNA检测套装，用于预测对阿片类药物上瘾的易感性。
Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that Laboratory Services MSO, LLC ("LSM") has launched a direct-to-consumer and non-invasive DNA test in the U.S. that tests for potential predisposition to opioid dependence. To purchase or find out more information, please visit . Avalon owns a 40% equity interest in LSM.
Avalon GloboCare Corp.（以下简称“公司”）（纳斯达克：ALBT）是一家开发创新电芯技术，细胞疗法和精准诊断的公司。今天宣布，实验室服务MSO，LLC（以下简称LSM）在美国推出了直接面向消费者的非侵入性DNA检测，用于检测可能存在的对阿片类药物依赖的易感性。要购买或了解更多信息，请访问www.labcorp.com/opioid-risk。Avalon在LSM拥有40％的股权。